#AUA14 - Poster: Long-term efficacy and safety of repeat onabotulinumtoxinA treatment in overactive bladder syndrome and urinary incontinence: Third interim analysis, median 2.4 years follow-up

ORLANDO, FL USA (UroToday.com) - Presented by Victor Nitti,¹ Christopher Chapple,² David Sussman,³ Sidney Radomski,⁴ Peter Sand,⁵ Steven Guard,⁶ Christopher Nardo,⁷ Jihao Zhou,⁸ and Karl-Dietrich Sievert⁹ at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

¹New York University, New York, NY, USA; ²Royal Hallamshire Hospital, Sheffield, UK; ³NJ School of Osteopathic Medicine, Newark, NJ, USA; ⁴University of Toronto, Toronto, ON, Canada; ⁵University of Chicago, Chicago, IL, USA; ⁶Allergan, Ltd., Marlow, UK; ⁷Allergan, Inc., Irvine, CA, USA; ⁸Allergan, Inc., Bridgewater, NJ, USA; ⁹University of Tuebingen, Tuebingen, Germany